Login to Your Account



Financings Roundup

With PolyHeme Work Under Way, Northfield Stock Sale Gets $67M

By Randall Osborne


Monday, February 7, 2005
Following last summer's go-ahead for its Phase III trial of PolyHeme, a hemoglobin-based oxygen carrier for hemorrhagic shock brought about by severe injury, Northfield Laboratories Inc. has priced an offering of 4.5 million shares at $15 each, for gross proceeds of about $67.5 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription